| Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH): An Algorithmic Approach in an Era of New Treatments |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
|
Experimental Hematology |
Myelodysplastic Syndromes (MDS) |
| Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
|
Experimental Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Advances and challenges in the treatment of myelodysplastic syndromes |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
|
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
| Pharmacologic progress in higher-risk MDS: an uphill battle |
|
Expert Opinion on Pharmacotherapy |
Myelodysplastic Syndromes (MDS) |
